"Families of Spinal Muscular Atrophy (FSMA), a non-profit organization with the mission of accelerating the identification of a treatment for SMA, began their relationship with Dr. Furman and Paracelsus in 2007... "
Families of SMA
Jill Jarecki, PhD

Company Profile

The comprehensive nonclinical testing program required to support clinical development and ultimate registration of a novel therapeutic involves years of work and many different types of studies. This nonclinical program - which begins prior to initiation of clinical trials and often continues after a drug is approved for marketing - is an essential component of the pharmaceutical R&D process and represents a considerable financial investment to the innovator.

Proficient design and support of nonclinical testing programs requires a customized and integrative strategy that is relevant to the intended clinical indication and acceptable to global health authorities.

Paracelsus can help your organization successfully meet this challenge by offering a range of professional consulting services.  Discipline-specific expertise in key areas such as toxicology, veterinary pathology, pharmacology, pharmacokinetics, and regulatory affairs (strategic and operational) is available to Paracelsus clients through highly knowledgeable and experienced professionals.